50 Most Trustworthy Companies of the Year 2019

Unlocking the Power of the Genome - Illumina


As a global company that places a high value on collaborative interactions, rapid delivery of solutions, and providing the highest level of quality, Illumina strives to meet this challenge.

Illumina innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics. Sequencing and array-based solutions for the analysis of genetic variation and function, in fields ranging from cancer research to agriculture

Driving Innovation

As a startup, Illumina aspired to transform human health. Its initial products enabled researchers to explore DNA at an entirely new scale, helping them create the first map of gene variations associated with health, disease, and drug response. Every breakthrough opened up a new world and showed it how much further there is to go.

Finding Answers

While the rate of progress is accelerating exponentially, it is only beginning to understand the clinical significance of the genome. What causes a cancer cell to mutate? What is the origin of a puzzling disease? Is it possible to prevent the next outbreak? Or safeguard the world’s food supply? These are just a few of the challenges that inspire it to push the boundaries of its imagination.

Making a Difference Now

Today Illumina is a global leader in genomics – an industry at the intersection of biology and technology. At the most fundamental level, it enables its customers to read and understand genetic variations. The firm strives to make its solutions increasingly simple, more accessible, and always reliable. As a result, discoveries that were unimaginable even a few years ago are now becoming routine – and are making their way into patient treatment.

Empowering a Healthy Future

Illumina now can sequence on an unprecedented scale. Collectively, this will give it a much deeper understanding of genetics than ever before. The company will begin to truly unlock the power of the genome. These advances will trigger a fundamental shift in healthcare and beyond. Medicine will continue to become more preventive and more precise. The firm will be healthier, longer. Illumina has only just begun.

Few Products of the Firm

Illumina sequencing platforms

It's innovative next-generation sequencing (NGS) platforms deliver exceptional data quality and accuracy, on a massive scale. View benchtop and production-scale sequencer comparison tables, and find tools designed to help you choose the right platform for your needs.

Cutting-edge array scanners

Illumina array scanning systems deliver rapid, sensitive, and accurate imaging of Illumina microarrays for exceptional genetic analysis results.

IVD Instruments Tailored for Clinical Labs

Explore in vitro diagnostic (IVD) instruments designed for the clinical lab environment. With easy-to-follow workflows and integrated software, our IVD instruments deliver accurate, reliable screening and diagnostic testing. Clinical labs can develop and perform their next-generation sequencing (NGS) tests, run predefined gene panels, or pursue a variety of clinical research applications.

The Face of the Firm

Francis deSouza | President & Chief Executive Officer

Francis deSouza was appointed President & CEO of Illumina in 2016 and is responsible for directing all aspects of company strategy, planning, and operations. He initially joined the company as President in 2013 and led Illumina’s business units and core functions responsible for envisioning, developing and producing the company’s products.

Previously, deSouza served as President of Products and Services at Symantec Corporation, where he was responsible for driving the vision for the company’s market-leading portfolio and served in a variety of executive roles. He joined Symantec through the acquisition of IMlogic, where he was co-founder and CEO.

Before joining IMlogic, deSouza was co-founder and CEO of Flash Communications, a provider of corporate instant messaging that was acquired by Microsoft. Following the acquisition, he joined Microsoft and led the team responsible for the development of the company’s enterprise real-time collaboration offerings. Currently, he is a member of the board of directors for The Walt Disney Company.

Francis deSouza received a B.S. and M.S. in Electrical Engineering and Computer Science from the Massachusetts Institute of Technology.

“Our goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. It is mission-critical for us to deliver innovative, flexible, and scalable solutions to meet the needs of our customers.”